Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORLUX in Psychotic Major Depression
NCT00146523Phase 3Completed
- Sponsor
- Corcept Therapeutics
- Start
- May 2005
- Primary completion
- Jul 2006
- Modality
- Orthosteric Ligands
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder with psychotic features comparing Mifepristone Arm with Placebo Arm (2 arms). Primary endpoint: The change in a measure of psychosis at 56 days. Started May 2005; status: completed.
02
Drugs
mifepristone
03
Conditions
major depressive disorder with psychotic features
Beyond the preview
Go deeper on NCT00146523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00146523.